Pd11-07 Chemoprophylaxis During Transrectal Prostate Needle Biopsy: Interim Analysis of Randomized Clinical Trial (Nct02423759)

Abstract

within 2 hours of one other for each patient to identify ureteral patency, the primary outcome for this study. Results from both imaging studies were reviewed in a blinded fashion by two experienced radiologists and compared.RESULTS: Eighty-six imaging studies were performed in 76 patients during the study period from September 2015 to September 2016. Females (58.3%) predominated males (41.7%) with a mean age of 51.2AE16.1 years and a mean body mass index of 29.6AE8.4 kg/m 2 . Four studies were excluded due to technical factors preventing imaging interpretation. For the remaining 82 studies, 66 (80.5%) demonstrated concordance for detecting ureteral patency between the two imaging techniques. Within the 16 (19.5%) discordant studies,15 showed antegrade urine flow on contrast-enhanced ultrasound but not on fluoroscopic nephrostogram, and one antegrade flow on fluoroscopic nephrostogram but not on ultrasound. For discordant studies, 97.5% of tubes were managed according to ultrasound results. No adverse events were noted related to any contrast-enhanced ultrasound studies. While contrast-enhanced ultrasound utilized no ionizing radiation, fluoroscopic nephrostograms provided a mean radiation exposure dose of 13.1AE17.5 mGycm 2 for patients.CONCLUSIONS: Contrast-enhanced ultrasound can be used to perform a nephrostogram with ultrasound contrast administered via a nephrostomy tube. This novel imaging technique is non-inferior to fluoroscopic nephrostogram, safe for patients, and devoid of radiation exposure in evaluating ureteral patency following percutaneous nephrolithotomy.